@article{c6262df8d2e548f8bc3bd6f4b05d1c85,
title = "Comparative effectiveness of first-line nab-paclitaxel versus paclitaxel monotherapy in triple-negative breast cancer",
abstract = "Aim: This observational study evaluated the effectiveness of nab-paclitaxel versus paclitaxel monotherapy as first-line (1L) treatment for metastatic triple-negative breast cancer (mTNBC). Materials & methods: 200 patients from the US Flatiron Health electronic health record-derived database (mTNBC diagnosis, January 2011-October 2016) who received 1L nab-paclitaxel (n = 105) or paclitaxel (n = 95) monotherapy were included. Overall survival and time to next treatment were evaluated. Results: The adjusted overall survival hazard ratio was 0.98 (95% CI: 0.67-1.44), indicating a similar risk of death between groups. Adjusted time to next treatment hazard ratio was 0.89 (95% confidence interval: 0.62-1.29). Conclusion: Nab-paclitaxel and paclitaxel monotherapy showed similar efficacy, suggesting their interchangeability as 1L treatments for mTNBC.",
keywords = "comparative effectiveness, first-line treatment, metastatic triple-negative breast cancer, nab-paclitaxel, paclitaxel",
author = "Patricia Luhn and Chui, {Stephen Y.} and Hsieh, {Angela Fu Chi} and Jingbo Yi and Almut Mecke and Bajaj, {Preeti S.} and Waseem Hasnain and Adeline Falgas and Ton, {Thanh G.N.} and Kurian, {Allison W.}",
note = "Funding Information: P Luhn, SY Chui, AFC Hsieh, PS Bajaj, W Hasnain, TGN Ton are Genentech/Roche employees and Roche stockholders. In addition, SY Chui has a patent, Diagnostic and Therapeutic Methods for Triple-Negative Breast Cancer (62/734677) pending. A Mecke and A Falgas are F. Hoffmann-La Roche employees and Roche stockholders. J Yi was employed by Genesis Research at the time of the analysis. AW Kurian reports research funding to her institution from Myriad Genetics for an unrelated project. This study was sponsored by F. Hoffmann-La Roche, Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Funding Information: Medical writing assistance for this manuscript was provided by J Men of Health Interactions and funded by F. Hoffmann-La Roche, Ltd. Publisher Copyright: {\textcopyright} 2019 Future Medicine Ltd.",
year = "2019",
doi = "10.2217/cer-2019-0077",
language = "English (US)",
volume = "8",
pages = "1173--1185",
journal = "Journal of Comparative Effectiveness Research",
issn = "2042-6305",
publisher = "Future Medicine Ltd.",
number = "14",
}